{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T07:11:20Z","timestamp":1776150680343,"version":"3.50.1"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Anxiety Disorders"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.janxdis.2026.103147","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T16:52:40Z","timestamp":1772038360000},"page":"103147","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Efficacy and safety of etifoxine versus alprazolam in generalized anxiety disorders with somatic symptoms: A randomized, double-blind, comparative study"],"prefix":"10.1016","volume":"119","author":[{"given":"Kalmegh","family":"Prabhakar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gopalakrishnan","family":"Ganesan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dhananjay","family":"Chaudhari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nitin","family":"Dalaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashish","family":"Mohide","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Spandan","family":"Thaker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mithun","family":"Dutta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bharati","family":"Patil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asish","family":"Mukhopadhyay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uma Jyothi","family":"Neeli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashutosh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajagopal","family":"Rajendra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raisa","family":"Shaikh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shruti","family":"Saha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5481-7780","authenticated-orcid":false,"given":"Supriya","family":"Sonowal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sapan","family":"Behera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prashant","family":"Devkare","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sucheta","family":"Pandit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dipak","family":"Patil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pravin","family":"Ghadge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lalit","family":"Lakhwani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suyog","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sadhna","family":"Joglekar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.janxdis.2026.103147_bib1","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1186\/s12888-025-06707-5","article-title":"Exploring generalized anxiety disorder symptoms: key insights from a population-based study in Iran","volume":"25","author":"Alipour","year":"2025","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.janxdis.2026.103147_bib2","unstructured":"American Psychiatric Association. (2023). What are anxiety disorders?. Available from: \u3008https:\/\/www.psychiatry.org\/patients-families\/anxiety-disorders\/what-are-anxiety-disorders\u3009. Accessed on 25 August 2025."},{"issue":"1","key":"10.1016\/j.janxdis.2026.103147_bib3","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0165-0327(99)00092-0","article-title":"Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability","volume":"58","author":"Anderson","year":"2000","journal-title":"Journal of Affective Disorders"},{"issue":"1","key":"10.1016\/j.janxdis.2026.103147_bib4","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3344\/kjp.2015.28.1.4","article-title":"Etifoxine for pain patients with anxiety","volume":"28","author":"Choi","year":"2015","journal-title":"The Korean Journal of pain"},{"issue":"2","key":"10.1016\/j.janxdis.2026.103147_bib5","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/fcp.12169","article-title":"Safety profile of etifoxine: A French pharmacovigilance survey","volume":"30","author":"Cottin","year":"2016","journal-title":"Fundamental & Clinical pharmacology"},{"issue":"2","key":"10.1016\/j.janxdis.2026.103147_bib6","first-page":"157","article-title":"Generalized Anxiety Disorder and Panic Disorder in Adults","volume":"106","author":"DeGeorge","year":"2022","journal-title":"American family Physician"},{"key":"10.1016\/j.janxdis.2026.103147_bib7","unstructured":"European Medicines Agency. (2022). Etifoxine Assessment Report. Available from: \u3008https:\/\/www.ema.europa.eu\/en\/documents\/referral\/etifoxine-containing-medicinal-products-article-31-referral-public-assessment-report-including-divergent-positions-chmp-opinion_en.pdf\u3009. Accessed 25 August 2025."},{"issue":"1","key":"10.1016\/j.janxdis.2026.103147_bib8","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.4103\/0019-5545.196975","article-title":"Clinical Practice Guidelines for the Management of Generalised Anxiety Disorder (GAD) and Panic Disorder (PD)","volume":"59","author":"Gautam","year":"2017","journal-title":"Indian Journal of Psychiatry"},{"issue":"8","key":"10.1016\/j.janxdis.2026.103147_bib9","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1080\/14656566.2018.1472767","article-title":"Comparing the efficacy of benzodiazepines and serotonergic anti-depressants for adults with generalized anxiety disorder: a meta-analytic review","volume":"19","author":"Gomez","year":"2018","journal-title":"Expert Opinion on pharmacotherapy"},{"issue":"9","key":"10.1016\/j.janxdis.2026.103147_bib10","doi-asserted-by":"crossref","first-page":"3783","DOI":"10.1017\/S0033291723001630","volume":"53","author":"Gosmann","year":"2023","journal-title":"Psychological Medicine"},{"key":"10.1016\/j.janxdis.2026.103147_bib11","unstructured":"Health Canada \u2013 Government of Canada. (2018). Alprazolam tablets, USP: Product monograph. Available from \u3008https:\/\/pdf.hres.ca\/dpd_pm\/00043878.PDF\u3009. Accessed 20 February 2026."},{"issue":"6","key":"10.1016\/j.janxdis.2026.103147_bib12","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1007\/s11920-014-0450-3","article-title":"Cross-cultural aspects of anxiety disorders","volume":"16","author":"Hofmann","year":"2014","journal-title":"Current Psychiatry Reports"},{"issue":"2","key":"10.1016\/j.janxdis.2026.103147_bib13","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S2215-0366(19)30475-4","article-title":"The burden of mental disorders across the states of India: the Global Burden of Disease Study 1990-2017","volume":"7","author":"India State-Level Disease Burden Initiative Mental Disorders Collaborators","year":"2020","journal-title":"The Lancet Psychiatry"},{"issue":"2","key":"10.1016\/j.janxdis.2026.103147_bib14","doi-asserted-by":"crossref","first-page":"117","DOI":"10.31887\/DCNS.2017.19.2\/rparikh","article-title":"Cultural aspects of anxiety disorders in India","volume":"19","author":"Khambaty","year":"2017","journal-title":"Dialogues in Clinical Neuroscience"},{"issue":"3","key":"10.1016\/j.janxdis.2026.103147_bib15","first-page":"433","article-title":"Analysis of Antidepressant, Benzodiazepine Anxiolytic, and Hypnotic Use When Treating Depression, Anxiety, and Aggression in Pain Clinic Patients Treated for Neuropathic Pain","volume":"12","author":"Kolacz","year":"2022","journal-title":"Life (Basel, Switzerland)"},{"issue":"1","key":"10.1016\/j.janxdis.2026.103147_bib16","doi-asserted-by":"crossref","first-page":"109","DOI":"10.53378\/meir.154","article-title":"Prevalence of anxiety and depression among young adults in India: A descriptive analysis","volume":"2","author":"Kumar","year":"2025","journal-title":"Management, Education & Innovation Review"},{"issue":"3","key":"10.1016\/j.janxdis.2026.103147_bib17","article-title":"Stigma and mental health in Indian society: A literature review","volume":"7","author":"Mallik","year":"2025","journal-title":"International Journal for Multidisciplinary Research (IJFMR)"},{"issue":"1","key":"10.1016\/j.janxdis.2026.103147_bib18","doi-asserted-by":"crossref","DOI":"10.1136\/bmjment-2022-300630","article-title":"Placebo response in trials with patients with anxiety, obsessive-compulsive and stress disorders across the lifespan: a three-level meta-analysis","volume":"26","author":"Motta","year":"2023","journal-title":"BMJ Mental Health"},{"key":"10.1016\/j.janxdis.2026.103147_bib19","unstructured":"National Institute for Health and Care Excellence. (2020). Generalised anxiety disorder and panic disorder in adults: management. Available from: \u3008https:\/\/www.nice.org.uk\/guidance\/cg113\/resources\/generalised-anxiety-disorder-and-panic-disorder-in-adults-management-pdf-35109387756997\u3009. Accessed 25 August 2025."},{"issue":"3","key":"10.1016\/j.janxdis.2026.103147_bib20","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/hup.757","article-title":"Efficacy of etifoxine compared to lorazepam monotherapy in the treatment of patients with adjustment disorders with anxiety: a double-blind controlled study in general practice","volume":"21","author":"Nguyen","year":"2006","journal-title":"Human Psychopharmacology"},{"issue":"2","key":"10.1016\/j.janxdis.2026.103147_bib21","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1001\/jamapsychiatry.2014.1763","article-title":"Benzodiazepine use in the United States","volume":"72","author":"Olfson","year":"2015","journal-title":"JAMA Psychiatry"},{"issue":"5","key":"10.1016\/j.janxdis.2026.103147_bib22","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1159\/000514524","volume":"28","author":"Parewa","year":"2021","journal-title":"Complementary Medicine Research"},{"key":"10.1016\/j.janxdis.2026.103147_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2025.1682400","article-title":"Efficacy of acupuncture versus sham acupuncture on generalized anxiety disorder: a meta-analysis of randomized controlled trials","volume":"16","author":"Jiang","year":"2025","journal-title":"Frontiers in Neurology"},{"issue":"sup1","key":"10.1016\/j.janxdis.2026.103147_bib24","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1080\/15622975.2018.1468030","article-title":"Anxiolytics targeting GABAA receptors: Insights on etifoxine","volume":"19","author":"Poisbeau","year":"2018","journal-title":"The World Journal of Biological Psychiatry: the Official Journal of the World Federation of Societies of Biological Psychiatry"},{"issue":"1","key":"10.1016\/j.janxdis.2026.103147_bib25","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1176\/ajp.140.1.82","article-title":"A controlled clinical trial of alprazolam for the treatment of anxiety","volume":"140","author":"Rickels","year":"1983","journal-title":"The American Journal of Psychiatry"},{"issue":"12","key":"10.1016\/j.janxdis.2026.103147_bib26","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1002\/da.22433","article-title":"Influence of study design on treatment response in anxiety disorder clinical trials","volume":"32","author":"Rutherford","year":"2015","journal-title":"Depression and Anxiety"},{"issue":"6","key":"10.1016\/j.janxdis.2026.103147_bib27","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/S2215-0366(23)00153-0","article-title":"Cultural adaptation of interventions for common mental disorders","volume":"10","author":"Sit","year":"2023","journal-title":"The Lancet Psychiatry"},{"issue":"1","key":"10.1016\/j.janxdis.2026.103147_bib28","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s12325-015-0176-6","article-title":"Etifoxine versus alprazolam for the treatment of adjustment disorder with anxiety: a randomized controlled trial","volume":"32","author":"Stein","year":"2015","journal-title":"Advances in Therapy"},{"issue":"sup1","key":"10.1016\/j.janxdis.2026.103147_bib29","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1080\/15622975.2018.1492736","article-title":"Pharmacotherapy of adjustment disorder: A review","volume":"19","author":"Stein","year":"2018","journal-title":"The World Journal of Biological Psychiatry: the Official Journal of the World Federation of Societies of Biological Psychiatry"},{"issue":"24","key":"10.1016\/j.janxdis.2026.103147_bib30","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1001\/jama.2022.22744","article-title":"Anxiety Disorders: A Review","volume":"328","author":"Szuhany","year":"2022","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.janxdis.2026.103147_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2018.e00688","article-title":"Patterns of benzodiazepines use in primary care adults with anxiety disorders","volume":"4","author":"Tanguay Bernard","year":"2018","journal-title":"Heliyon"},{"key":"10.1016\/j.janxdis.2026.103147_bib32","unstructured":"The European Medicines Agency. (2005). Committee for medicinal products for human use (CHMP) guideline on the clinical investigation of medicinal products indicated for generalised anxiety disorder. 2005. Available from: \u3008https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-clinical-investigation-medicinal-products-indicated-generalised-anxiety-disorder_en.pdf\u3009. Accessed on 25 August 2025."},{"issue":"11","key":"10.1016\/j.janxdis.2026.103147_bib33","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.1007\/s00213-020-05617-6","article-title":"Etifoxine is non-inferior than clonazepam for reduction of anxiety symptoms in the treatment of anxiety disorders: a randomized, double blind, non-inferiority trial","volume":"237","author":"Vicente","year":"2020","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.janxdis.2026.103147_bib34","unstructured":"World Health Organization. (2022). Mental disorders. Available from: \u3008https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/mental-disorders\u3009. Accessed on 25 August 2025."},{"key":"10.1016\/j.janxdis.2026.103147_bib35","unstructured":"World Health Organization. (2025). Anxiety disorders. Available from: \u3008https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/anxiety-disorders\u3009. Accessed on 12 September 2025."},{"key":"10.1016\/j.janxdis.2026.103147_bib36","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jad.2024.12.086","article-title":"Trends in the epidemiology of anxiety disorders from 1990 to 2021: A global, regional, and national analysis with a focus on the sociodemographic index","volume":"373","author":"Wu","year":"2025","journal-title":"Journal of Affective Disorders"}],"container-title":["Journal of Anxiety Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0887618526000393?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0887618526000393?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T06:34:52Z","timestamp":1776148492000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0887618526000393"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":36,"alternative-id":["S0887618526000393"],"URL":"https:\/\/doi.org\/10.1016\/j.janxdis.2026.103147","relation":{},"ISSN":["0887-6185"],"issn-type":[{"value":"0887-6185","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of etifoxine versus alprazolam in generalized anxiety disorders with somatic symptoms: A randomized, double-blind, comparative study","name":"articletitle","label":"Article Title"},{"value":"Journal of Anxiety Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.janxdis.2026.103147","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103147"}}